Several months ago, Maybank reached a high of almost RM8.90 while Genting was hovering at around RM5.10. Maybank is trading at around RM8.70 today. Including the 30 sen a share dividend just received, Maybank's actual price should be RM9 a share for a gain of 1% over its peak price several months ago. Including the 9 sen a share dividend, Genting's price should be RM4.78 for a decline of about 6%. It is obvious to everyone which counter has performed better.
KUALA LUMPUR The Tourism, Arts and Culture Ministry has successfully lured 450,000 tourists from China after the signing of two agreements during Prime Minister Datuk Seri Anwar Ibrahim's official visit to the country last month, says Datuk Seri Tiong King Sing (pic).
The minister said the success was the result of the promotion done by Tourism Malaysia in conjunction with the Prime Minister’s visit to Beijing, China on March 29.
Someone here had bragged about his success in investments in Genting, raking in over 25% profit a year when no one can verify his claim. What I wrote about Maybank are all facts readily available on the internet. Let's compare Maybank and Genting's share prices at the beginning of 2020 and see what counter has performed much better.
Posted by James_Bond > 14 minutes ago | Report Abuse Serve the sourgrapes (Bob, AngTayKor etc) right! Haha… ---------------------
Please la sour grapes over your 90m rupiah? Still angry with ATK for exposing your shameless lies here? Hahaha....
Please la, ATK bought 1m GenB shares at 2.97 at early Nov 2020, made over 60% in less than 2 months. ATK had abt 10 rounds of profits trading this stock over the past couple of years with 2 rounds of minor losses. At above 5.00 Justborn still buying non-stop. Ha!
Let me post your shameless lies here again in case you forget:
Posted by James_Bond > 2 months ago | Report Abuse 3 million ringgit ready to scoop this Genting Berhad mammoth! -------------------------- Posted by James_Bond > 2 months ago | Report Abuse USD 3 million fresh fund ready to scoop Genting Berhad! Cheers! -------------------------- Posted by James_Bond > 4 weeks ago | Report Abuse I hv near RM 90million cash to buy Genting Berhad! -------------------------- Posted by James_Bond > 4 weeks ago | Report Abuse 90+ million cash in hand, I m not afraid at all!
"Another surge for Genting when people reinvesting using dividend" To buy 1,000 Genting shares using the 9 sen dividend, one would need to own more than 50,000 Genting shares.
Gone are days buy GB, Fast & Sure profits. GB grp big & fast devt, heavy & high debts. Big % of revenue goes to repay debt. Amortization, int, depreciation also big.
HIGH CEO PAY whether co make or lose $. RPTs also need to be considered. Overall profitability is affected.
Solution CEO's max salary is RM10M. CEO gets pay fr 2 PLC's ONLY. RPT is NOT allowed. External committee approve >rm100m deals.
For Sure, GB grp stks will rise faster, higher, quicker.
Generally to stock suffers from poor governance. CEO salary is a classic example as well as share transactions mostly dumping following random announcements. Yet there is lot of foreign institutional shareholding. Wish Genting was US listed it would be forced to be more transparent and abide by good governance. Not that US is capital of good governance!
Sorry paying dividends alone does not mean it is blue chip! The dividend yield is relatively low compared to its sector…most people invested in the shares are hoping for good capital return.
After Ramadan, a team of Taurx personnel will be flying over to a country (a prelude to their C.A) to show their doctors how to accurately diagnose AD using modern brain PET scan technology. Tau pathology PET scan can accurately diagnose and predict AD progression, something that amyloid pathology PET scan is unable to do. This is because Tau is the cause and driver of AD. When there is no tau accumulation inside the brain, there is no AD, even when the brain is full of amyloid deposits. When the Tau accumulates and start to spread across the brain and spread to which region in the brain, we know the stage and severity of the patient's AD now, and we are able to accurately predict the AD severity 1 year to 5 years later using computer simulation. We knew this fact over 30 years ago (when PET scan technology was not available then). We did this by slicing hundreds of donated brains from brain bank collection, then comparing normal brain of the deceased VS confirmed AD brain of the deceased, then comparing their Tau pathology progress. Very accurate diagnosis. Now the advancement of PET scan technology allows us to do this on living patients. To determine their stage of Tau pathology and progress of AD. Very powerful. Global AD pandemic can be halted with HMTM.
How I wish Genting share up more than 5+, has been holding Genting shares for months… other than the small piece of dividend and small capital gain, nothing else… Guess should stop dreaming, and it’s time to wake up MM! Covid striking back! State elections coming! Global recession with many uncertainty ahead… hard, hard, hard… Investing in other momentum shares hv better yield than Genting Berhad…
Posted by James_Bond > 1 month ago | Report Abuse Will support Genting Berhad with all my funds! Hv faith in Genting Berhad and you will be rewarded greatly! Mark my words! Turbocharged Engine 7. Genting is your Best of the best investment in 2023. Creme de la creme. Be patience and you will be rewarded greatly with Genting! I follow the philosophy of Warren Buffet, investing in GREAT BUSINESSES at right price! ----------- Posted by James_Bond > 2 hours ago | Report Abuse … Guess should stop dreaming, and it’s time to wake up MM! Covid striking back! State elections coming! Global recession with many uncertainty ahead… hard, hard, hard… Investing in other momentum shares hv better yield than Genting Berhad… --------------------------------------------
Please la still want to preach abt Warren Buffett style of investing. Duno how many waves of covid spikes already but now all casinos are fully opened and days of lockdowns are over. I remember during strict covid lockdown 2 years ago, this stock ever hit 5.50. State elections got anything to do with highlands operating as a going-concern? Will Warren Buffett sell because of non-events like increase in covid cases and state elections?
Must be bought the shares liow promote nonstop. Sold the shares liow do fear mongering. Dont disgrace the good name of Warren Buffett here la. Tsk Tsk Tsk....
1) wanna buy low, spread fear. 2) after buy, promote to push up price. 3) when price higher, sell & take profit. 4) repeat steps 1 - 3 again & again always. 5) common approach by lousy fellas. 6) few here doing this with their posts. 7) read & you can know who they are.
Four senior FDA leaders forged close ties with Biogen well ahead of Aduhelm's approval. Now they've left FDA
Two years after the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm, four of the top agency officials who came under scrutiny for their close relationship with the drugmaker during the approval process have left the agency.
Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers. The landing spot for the fourth, Billy Dunn, former director of the Division of Neurology Products, has yet to be made public.
Aduhelm, or aducanumab, ended up a commercial flop, but opened the door for Eisai and Biogen’s follow-on Alzheimer’s drug Leqembi, which will likely be a blockbuster. But the approval of the drug, struggles to get it reimbursed at CMS and nationwide, and the investigations that followed, continue to have an impact on not just Biogen but the entire industry.
According to the House Committee on Oversight and Reform and Committee on Energy and Commerce’s investigation into the Biogen and FDA relationship, the company and agency officials met in July 2019, a full year before Biogen would even complete its submission for aducanumab, and as part of a workstream outside of a typical application’s review.
Almost four months prior to this first meeting, Biogen in March 2019 announced publicly it was shuttering two Phase III trials, effectively ending development on aducanumab, as a futility analysis conducted by an independent data monitoring committee indicated that they were unlikely to meet their primary endpoint.
Dunn, who led the efforts around aducanumab and started at the FDA’s division of neurological products in 2005 before rising to the top of the office in 2020, in late February decided to leave the agency, effective immediately and with little explanation.
It’s still unclear where he will end up, and the Alzheimer’s Association of America and his former deputy Eric Bastings, who moved over to Ionis as a VP, told Endpoints News they don’t know where Dunn is headed. Endpoints was unable to reach Dunn directly for comment.
Bastings previously told Endpoints of his own departure, “The opportunity with Ionis is why I chose to retire from the FDA,” but he said he could not comment on his role in the Aduhelm-related investigations.
Meanwhile, FDA’s Kun Jin, after more than 27 years at the agency, in March was named VP and head of biostatistics at Anavex Life Sciences. And earlier this week, Biohaven, a clinical-stage biopharma company, named Nick Kozauer, former acting deputy director of the FDA’s division of neurology products and 8-year FDA vet, as SVP for clinical development and regulatory strategy.
Neither responded to requests for comment.
Ranjit Mani, clinical team leader for Dunn’s neurology division, confirmed that he is still working at the FDA but declined to comment on the Aduhelm investigations. None of the others from FDA on the list from the congressional investigation responded to a request for comment. The only Biogen employee on the list, Samantha Budd Haeberlein, saw her employment as SVP end in mid-March but it’s unknown where she’s headed.
On why all four senior FDA leaders departed so quickly following the release of the December 2022 congressional investigation, an FDA spokesperson confirmed that all the others on the list still work at the agency, and added, “While we are unable to say specifically why the individuals left, CDER Staff leave the FDA for a variety of reasons.”
Bank promoters are cheering the removal of prosperity tax and rising interest rates ...but banking sector is in "crisis" .. Higher labor cost Higher bank interest rate Highly competitive business environment incl the digital banks Higher debts written off
GenB only gained around 25 sen (from RM4.40 to RM4.66) or 6% since the beginning of the year. YTL Power has gained almost 60% from RM0.71 to RM1.12 during the same period.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Michael_chan2022
3,349 posts
Posted by Michael_chan2022 > 2023-04-14 11:07 | Report Abuse
Singapore a magnet for China billionaires | THE B…:
https://youtu.be/yoyvHoJRpto
Maybank and CIMB should benefit also...
But I don't see any Public Bank in Singapore